Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Coeptis Therapeutics Holdings, Inc.

Get SEC filing alerts via email and in your feed for Coeptis Therapeutics Holdings, Inc.

COEP COEPW

Coeptis Therapeutics Holdings, Inc.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell and antibody therapies for cancer and viral infections. Its core activities include advancing natural killer (NK) cell platforms, CAR T-cell technologies, and diagnostic tools. The company collaborates with academic and industry partners to develop targeted treatments, aiming to improve efficacy and safety in oncology and infectious disease markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Coeptis Therapeutics Holdings, Inc.

1
1
Coeptis Therapeutics Holdings, Inc. Z Squared Inc. Reports 81% Revenue Increase Amid Strategic Shift to Digital Asset Mining

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Reports $1.36 Million Revenue in 2025, Faces Increased Losses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Reports Revenue Growth and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Reports Revenue Growth and Increased Operating Expenses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Reports First Quarter 2025 Financial Results with $62,874 in Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics Reports Significant Financial Changes, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments